Show simple item record

dc.contributor.authorAhomäki, I.
dc.contributor.authorPitkänen, V.
dc.contributor.authorSoppi, A.
dc.contributor.authorSaastamoinen, L.
dc.date.accessioned2020-07-01T10:17:00Z
dc.date.available2020-07-01T10:17:00Z
dc.date.issued2020
dc.identifier.citationAhomäki, I., Pitkänen, V., Soppi, A., & Saastamoinen, L. (2020). Impact of a physician-targeted letter on opioid prescribing. <i>Journal of Health Economics</i>, <i>72</i>, Article 102344. <a href="https://doi.org/10.1016/j.jhealeco.2020.102344" target="_blank">https://doi.org/10.1016/j.jhealeco.2020.102344</a>
dc.identifier.otherCONVID_35853246
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/71010
dc.description.abstractWe study the effect of a physician-targeted nudge letter on opioid prescribing. In May 2017, the Social Insurance Institution of Finland sent a personal information letter to all physicians who had issued a prescription containing at least 100 tablets of paracetamol-codeine combination to a new patient. The aim of the letter was to draw the physicians’ attention to their prescribing practices and to decrease the size of the first codeine prescription. Using individual level register data and a difference-in-differences strategy, we estimate that the letter decreased the average number of tablets purchased by new patients by 12.5 percent and the probability of a first purchase being at least 100 tablets by six percentage points. We also find that these effects were larger among consistent high prescribers. However, we do not find similar effects on other mild or strong opioids.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJournal of Health Economics
dc.rightsCC BY-NC-ND 4.0
dc.subject.otherreseptilääkkeet
dc.subject.otherKELA
dc.subject.otherKansaneläkelaitos
dc.subject.otheropioid prescribing
dc.subject.otherinformation letter
dc.subject.otherprescription drugs
dc.subject.otherdifference-in-differences
dc.titleImpact of a physician-targeted letter on opioid prescribing
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202007015193
dc.contributor.laitosKauppakorkeakoulufi
dc.contributor.laitosSchool of Business and Economicsen
dc.contributor.oppiaineTaloustiedefi
dc.contributor.oppiaineBasic or discovery scholarshipfi
dc.contributor.oppiaineEconomicsen
dc.contributor.oppiaineBasic or discovery scholarshipen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.description.reviewstatuspeerReviewed
dc.relation.issn0167-6296
dc.relation.volume72
dc.type.versionacceptedVersion
dc.rights.copyright© 2020 Elsevier B.V.
dc.rights.accesslevelopenAccessfi
dc.relation.grantnumber12/26/2019
dc.subject.ysopalaute
dc.subject.ysolääkkeet
dc.subject.ysolääkemääräykset
dc.subject.ysoohjeet
dc.subject.ysoopioidit
dc.subject.ysolääketurvallisuus
dc.subject.ysolääkärit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p1236
jyx.subject.urihttp://www.yso.fi/onto/yso/p1077
jyx.subject.urihttp://www.yso.fi/onto/yso/p5840
jyx.subject.urihttp://www.yso.fi/onto/yso/p9583
jyx.subject.urihttp://www.yso.fi/onto/yso/p6030
jyx.subject.urihttp://www.yso.fi/onto/yso/p37935
jyx.subject.urihttp://www.yso.fi/onto/yso/p6182
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1016/j.jhealeco.2020.102344
dc.relation.funderKansaneläkelaitos (Kela)fi
dc.relation.funderSocial Insurance Institution of Finlanden
jyx.fundingprogramMuutfi
jyx.fundingprogramOthersen
jyx.fundinginformationIiro Ahomäki gratefully acknowledges funding from the Yrjö Jahnsson Foundation (grant No. 20197162) and from the Social Insurance Institution of Finland.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as CC BY-NC-ND 4.0